| Literature DB >> 28979312 |
Naser Foroughifar1, Somayeh Karimi Beromi1, Hoda Pasdar1, Masoumeh Shahi1.
Abstract
Heterocyclic compounds containing a pyrimidine nucleus are of special interests thanks to their applications in medicinal chemistry as they are the basic skeleton of several bioactive compounds such as antifungal, antibacterial, antitumor and antitubercular. As a part of our research in the synthesis of pyrimidine derivatives containing biological activities, some new tetrahydropyrimidine derivatives (1-10) were synthesized via Biginelli reaction using HCl or DABCO as a catalyst with good yields. All structures of products were confirmed by IR, 1H NMR and 13C NMR spectroscopy. The antibacterial activity of some synthesized compounds was investigated against Staphylococcusaureus (ATCC 6538), Staphylococcus epidermidis (ATCC 12228),Bacillus cereus (ATCC14579), Esherichia coli (ATCC 25922), Klebsiella pneumonia (ATCC 13883) and Pseudomonas aeruginosa (PAO1) bacteria. Some of these compounds such as 8 and 10 exhibited a good to significant antibacterial activity.Entities:
Keywords: Biginelli reaction; Tetrahydropyrimidine; antimicrobial activity
Year: 2017 PMID: 28979312 PMCID: PMC5603867
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Characterization data of tetrahydropyrimidine derivatives 1-10.
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|
|
|
|
|
| |||
| 197-200 | 70 | 45 | 4 | 7 | C6H5 | 1 |
| 178-180 | 72 | 63 | 5 | 7 | 4-Cl-C6H4 | 2 |
| 213-216 | 81 | 63 | 3 | 7 | 3,4-OMe2-C6H3 | 3 |
| 202-204 | 81 | 63 | 3 | 7 | 4-OMe-C6H4 | 4 |
| 179-182 | 88 | 53 | 4 | 7 | 4-Me-C6H4 | 5 |
| 226-228 | 71 | 52 | 4 | 7 | 3-NO2-C6H4 | 6 |
| 243-245 | 81 | 50 | 3 | 7 | 2-OH-C6H4 | 7 |
| 127-129 | 79 | 50 | 4 | 7 | 5-Br-2-OH-C6H3 | 8 |
| 211-213 | 70 | 62 | 4 | 7 | 4-ipr--C6H4 | 9 |
| 218-220 | 74 | 54 | 3 | 7 | 4-OH-C6H4 | 10 |
Reported yields are after recrystallization
Antibacterial activity of some synthesized compounds (inhibition zones, mm).
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| 1 | 20 | - | - | - | - | - |
| 2 | 15 | 30 | - | - | - | 15 |
| 3 | 14 | - | - | - | - | - |
| 4 | 10 | 18 | - | - | - | 5 |
| 6 | 15 | - | - | 10 | - | - |
| 8 | 45 | 58 | 32 | 45 | 39 | 50 |
| 9 | 15 | 25 | - | - | - | - |
| 10 | 14 | 22 | mutation | 15 | - | - |
|
| 34 | 35 | - | 29 | 26 | - |
Dimethyl sulfoxide (DMSO) only, control for compounds and references.
Reference compound
MIC values of some synthesized compounds
|
|
| |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 1 | 37 | 25 | NP | 95 | 120 | 100 |
| 2 | 45 | 25 | 120 | 80 | 105 | 50 |
| 3 | 45 | 95 | NP | 100 | NP | 65 |
| 4 | 20 | 15 | 110 | 100 | 100 | 120 |
| 6 | 45 | 80 | NP | 50 | 130 | 85 |
| 8 | 15 | 15 | 25 | 15 | 15 | 15 |
| 9 | 45 | 30 | NP | 95 | 110 | 70 |
| 10 | 45 | 15 | NP | 50 | 110 | NP |
|
| 10 | 15 | 50 | 23 | 15 | 46 |
NP: not performed
Reference compound
Scheme 1The synthetic pathway for preparation of tetrahydropyrimidine derivatives 1-10